Literature DB >> 24863754

Structural and biochemical characterization of the folyl-poly-γ-l-glutamate hydrolyzing activity of human glutamate carboxypeptidase II.

Michal Navrátil1, Jakub Ptáček, Pavel Šácha, Jana Starková, Jacek Lubkowski, Cyril Bařinka, Jan Konvalinka.   

Abstract

In addition to its well-characterized role in the central nervous system, human glutamate carboxypeptidase II (GCPII; Uniprot ID Q04609) acts as a folate hydrolase in the small intestine, participating in the absorption of dietary polyglutamylated folates (folyl-n-γ-l-glutamic acid), which are the provitamin form of folic acid (also known as vitamin B9 ). Despite the role of GCPII as a folate hydrolase, nothing is known about the processing of polyglutamylated folates by GCPII at the structural or enzymological level. Moreover, many epidemiologic studies on the relationship of the naturally occurring His475Tyr polymorphism to folic acid status suggest that this polymorphism may be associated with several pathologies linked to impaired folate metabolism. In the present study, we report: (a) a series X-ray structures of complexes between a catalytically inactive GCPII mutant (Glu424Ala) and a panel of naturally occurring polyglutamylated folates; (b) the X-ray structure of the His475Tyr variant at a resolution of 1.83 Å; (c) the study of the recently identified arene-binding site of GCPII through mutagenesis (Arg463Leu, Arg511Leu and Trp541Ala), inhibitor binding and enzyme kinetics with polyglutamylated folates as substrates; and (d) a comparison of the thermal stabilities and folate-hydrolyzing activities of GCPII wild-type and His475Tyr variants. As a result, the crystallographic data reveal considerable details about the binding mode of polyglutamylated folates to GCPII, especially the engagement of the arene binding site in recognizing the folic acid moiety. Additionally, the combined structural and kinetic data suggest that GCPII wild-type and His475Tyr variant are functionally identical.
© 2014 FEBS.

Entities:  

Keywords:  H475Y(1561C→T) polymorphism; arene-binding site; crystal structure; folate hydrolase 1; zinc metalloprotease

Mesh:

Substances:

Year:  2014        PMID: 24863754      PMCID: PMC6257983          DOI: 10.1111/febs.12857

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  36 in total

1.  Glutamate carboxypeptidase II: a polymorphism associated with lower levels of serum folate and hyperhomocysteinemia.

Authors:  A M Devlin; E H Ling; J M Peerson; S Fernando; R Clarke; A D Smith; C H Halsted
Journal:  Hum Mol Genet       Date:  2000-11-22       Impact factor: 6.150

2.  PRODRG: a tool for high-throughput crystallography of protein-ligand complexes.

Authors:  Alexander W Schüttelkopf; Daan M F van Aalten
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-07-21

Review 3.  Glutamate carboxypeptidase II: an overview of structural studies and their importance for structure-based drug design and deciphering the reaction mechanism of the enzyme.

Authors:  J Pavlícek; J Ptácek; C Barinka
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

4.  Molecular identification of β-citrylglutamate hydrolase as glutamate carboxypeptidase 3.

Authors:  François Collard; Didier Vertommen; Stefan Constantinescu; Lieven Buts; Emile Van Schaftingen
Journal:  J Biol Chem       Date:  2011-09-09       Impact factor: 5.157

Review 5.  Folic acid and L-5-methyltetrahydrofolate: comparison of clinical pharmacokinetics and pharmacodynamics.

Authors:  Klaus Pietrzik; Lynn Bailey; Barry Shane
Journal:  Clin Pharmacokinet       Date:  2010-08       Impact factor: 6.447

6.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

7.  Structural basis of interactions between human glutamate carboxypeptidase II and its substrate analogs.

Authors:  Cyril Barinka; Klara Hlouchova; Miroslava Rovenska; Pavel Majer; Miroslawa Dauter; Niyada Hin; Yao-Sen Ko; Takashi Tsukamoto; Barbara S Slusher; Jan Konvalinka; Jacek Lubkowski
Journal:  J Mol Biol       Date:  2008-01-05       Impact factor: 5.469

8.  Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II.

Authors:  Cyril Barinka; Miroslava Rovenská; Petra Mlcochová; Klára Hlouchová; Anna Plechanovová; Pavel Majer; Takashi Tsukamoto; Barbara S Slusher; Jan Konvalinka; Jacek Lubkowski
Journal:  J Med Chem       Date:  2007-06-14       Impact factor: 7.446

9.  Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer.

Authors:  Jeroen R Mesters; Cyril Barinka; Weixing Li; Takashi Tsukamoto; Pavel Majer; Barbara S Slusher; Jan Konvalinka; Rolf Hilgenfeld
Journal:  EMBO J       Date:  2006-02-09       Impact factor: 11.598

10.  MolProbity: all-atom structure validation for macromolecular crystallography.

Authors:  Vincent B Chen; W Bryan Arendall; Jeffrey J Headd; Daniel A Keedy; Robert M Immormino; Gary J Kapral; Laura W Murray; Jane S Richardson; David C Richardson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-12-21
View more
  10 in total

1.  Local enema treatment to inhibit FOLH1/GCPII as a novel therapy for inflammatory bowel disease.

Authors:  Abhijit A Date; Rana Rais; Taarika Babu; Jairo Ortiz; Pranjali Kanvinde; Ajit G Thomas; Sarah C Zimmermann; Alexandra J Gadiano; Gilad Halpert; Barbara S Slusher; Laura M Ensign
Journal:  J Control Release       Date:  2017-01-31       Impact factor: 9.776

2.  The Small Molecule Hyperphyllin Enhances Leaf Formation Rate and Mimics Shoot Meristem Integrity Defects Associated with AMP1 Deficiency.

Authors:  Olena Poretska; Saiqi Yang; Delphine Pitorre; Wilfried Rozhon; Karin Zwerger; Marcos Castellanos Uribe; Sean May; Peter McCourt; Brigitte Poppenberger; Tobias Sieberer
Journal:  Plant Physiol       Date:  2016-05-03       Impact factor: 8.340

Review 3.  Looking for Drugs in All the Wrong Places: Use of GCPII Inhibitors Outside the Brain.

Authors:  James J Vornov; Diane Peters; Mike Nedelcovych; Kristen Hollinger; Rana Rais; Barbara S Slusher
Journal:  Neurochem Res       Date:  2019-11-20       Impact factor: 3.996

4.  FOLH1/GCPII is elevated in IBD patients, and its inhibition ameliorates murine IBD abnormalities.

Authors:  Rana Rais; Weiwei Jiang; Huihong Zhai; Krystyna M Wozniak; Marigo Stathis; Kristen R Hollinger; Ajit G Thomas; Camilo Rojas; James J Vornov; Michael Marohn; Xuhang Li; Barbara S Slusher
Journal:  JCI Insight       Date:  2016-08-04

Review 5.  Metamorphosis of prostate specific membrane antigen (PSMA) inhibitors.

Authors:  Zahra Nikfarjam; Farshid Zargari; Alireza Nowroozi; Omid Bavi
Journal:  Biophys Rev       Date:  2022-01-13

Review 6.  The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.

Authors:  James C Evans; Meenakshi Malhotra; John F Cryan; Caitriona M O'Driscoll
Journal:  Br J Pharmacol       Date:  2016-09-23       Impact factor: 8.739

7.  Structural and biochemical characterization of a novel aminopeptidase from human intestine.

Authors:  Jan Tykvart; Cyril Bařinka; Michal Svoboda; Václav Navrátil; Radko Souček; Martin Hubálek; Martin Hradilek; Pavel Šácha; Jacek Lubkowski; Jan Konvalinka
Journal:  J Biol Chem       Date:  2015-03-09       Impact factor: 5.157

8.  Design of composite inhibitors targeting glutamate carboxypeptidase II: the importance of effector functionalities.

Authors:  Zora Novakova; Jiri Cerny; Cindy J Choy; Jessie R Nedrow; Joeseph K Choi; Jacek Lubkowski; Clifford E Berkman; Cyril Barinka
Journal:  FEBS J       Date:  2015-11-05       Impact factor: 5.542

9.  The Impact of Monosodium Glutamate on 68Ga-PSMA-11 Biodistribution in Men with Prostate Cancer: A Prospective Randomized, Controlled Imaging Study.

Authors:  Wesley R Armstrong; Andrei Gafita; Shaojun Zhu; Pan Thin; Kathleen Nguyen; Rejah Alano; Stephanie Lira; Kiara Booker; Linda Gardner; Tristan Grogan; David Elashoff; Martin Allen-Auerbach; Magnus Dahlbom; Johannes Czernin; Jeremie Calais
Journal:  J Nucl Med       Date:  2021-01-28       Impact factor: 11.082

Review 10.  Metal-Based PSMA Radioligands.

Authors:  Eleni Gourni; Gjermund Henriksen
Journal:  Molecules       Date:  2017-03-24       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.